FDA lifts par­tial hold on Curis' PhI/II leukemia study as biotech rais­es $15M 

Curis can now go full speed ahead with its leukemia tri­al af­ter the FDA had im­posed a par­tial clin­i­cal hold on the biotech last year due to a pa­tient death.

The com­pa­ny an­nounced Thurs­day that the FDA lift­ed a par­tial clin­i­cal hold on a Phase I/II tri­al eval­u­at­ing its leukemia treat­ment emavusert­ib. The reg­u­la­tor put two par­tial holds in place in April of last year af­ter a pa­tient died from rhab­domy­ol­y­sis, a com­pli­ca­tion that Curis had pre­vi­ous­ly iden­ti­fied as a safe­ty sig­nal where skele­tal mus­cle starts to break down in­to the blood. In Au­gust, it said some pa­tients could be en­rolled in the Phase Ia tri­al if they re­ceived a low­er dose of 200 mg.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER